Loading...
Please wait, while we are loading the content...
Similar Documents
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
| Content Provider | Scilit |
|---|---|
| Author | O'brien, Susan Parikh, Sameer A. Keating, Michael J. Wang, Xuemei Ferrajoli, Alessandra Faderl, Stefan Burger, Jan Koller, Charles Estrov, Zeev Badoux, Xavier Lerner, Susan Wierda, William G. |
| Copyright Year | 2011 |
| Description | Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum β-2 microglobulin (β2M) ≥ 4 mg/L. Sixty patients were enrolled; median age was 59 years (range, 42-69); 75% were male; median β2M was 5.1 mg/L (range, 4-11.6); and 51% were Rai III-IV. Complete remission (CR) was achieved in 70%, partial remission (PR) in 18%, nodular PR in 3%, for an overall response of 92%. Of 14 patients with 17p deletion, CR was achieved by 8 (57%). Of 57 BM samples evaluated by 3-color flow cytometry at the end of treatment, 41 (72%) were negative for residual disease. Grade 3-4 neutropenia and thrombocytopenia occurred with 33% and 13% courses, respectively. The median progression-free survival was 38 months and median OS was not reached. In conclusion, CFAR is an active frontline regimen for high-risk CLL. Response rates and survival are comparable with historic high-risk FCR-treated patients. CFAR may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081295/pdf |
| Ending Page | 2068 |
| Page Count | 7 |
| Starting Page | 2062 |
| DOI | 10.1182/blood-2011-01-329177 |
| Journal | Blood |
| Issue Number | 8 |
| Volume Number | 118 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2011-08-25 |
| Access Restriction | Open |
| Subject Keyword | Hematology Survival Alemtuzumab High Risk Lymphocytic Rituximab Cll Chemoimmunotherapy Cfar Frontline Journal: Blood (Vol- 105, Issue- 8) |
| Content Type | Text |
| Resource Type | Article |
